Navigation Links
GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
Date:10/20/2008

ich could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
2. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Nanoemulsion vaccines show increasing promise
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
7. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 ... trade association serving and representing the life sciences ... first Board of Directors meeting at The Foundry ... meeting of the organization brought together a broad ... region, and underscored the organization's early successes in ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Calif., Oct. 17 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... novel anticancer therapeutics, today announced that the,company ... Conference on,Molecular Targets and Cancer Therapeutics. This ... in San Francisco, California. Preliminary data ...
... call Wednesday, October 24, at 1:30 p.m. EDT, ... AVGN ), a biopharmaceutical company developing innovative ... its quarterly,conference call to discuss third quarter results ... (10:30 a.m. PDT). Kenneth Chahine, Chief Executive,Officer, and ...
... Calif. Carbon nanotubes have been employed for a ... and membranes. , While they have proven useful for ... going on at the molecular level. For example, how ... other on the atomic scale" Answering this question could ...
Cached Biology Technology:Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Researchers measure carbon nanotube interaction 2
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... macrophages, immune cells that can engulf and poison bacteria ... A new study from the University of Illinois disproves ... PLoS ONE , shows that macrophages focus their most ... targets outside the cytoplasm. Macrophages are voracious eaters ...
... research institutes, announced today the launch of three ... in extreme environments. The three selected genomes are ... and emperor penguin, and one altiplano animal: the ... carried out using Next-generation sequencing technologies, which have ...
... and drainage. Blood vessels feeding the tissues bring in ... While much is known about how blood vessels are ... Now though, Norrmn et al. have identified two of ... mouse embryo. The engineers are the transcription ...
Cached Biology News:New study overturns orthodoxy on how macrophages kill bacteria 2New study overturns orthodoxy on how macrophages kill bacteria 3Genome projects launched for three extreme-environment animals 2Genome projects launched for three extreme-environment animals 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... and Silencer Pre-designed siRNAs, which are already ...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: